<DOC>
	<DOCNO>NCT02591017</DOCNO>
	<brief_summary>34 adult ( &gt; 18 year ) cancer pain outpatient Opioid base therapy pain breakthrough pain extreme pain movement include prospective , randomize , double-blind crossover study . Over period 3 week patient go 3 treatment arm , one last one week : Group A receive morphine drop Placebo spray , Group B receive ketamine/chitosan spray nasal Placebo drop Group C receive morphine drop ketamine/chitosan spray nasal . Primary endpoint time onset action intranasal ketamine compare morphine drop . Secondary endpoint median numeric rating scale ( NRS ) improvement use spray morphine combination ketamine spray morphine drop .</brief_summary>
	<brief_title>Comparison Oral Morphine Versus Nasal Ketamine Spray With Chitosan Cancer Pain Outpatients</brief_title>
	<detailed_description />
	<mesh_term>Breakthrough Pain</mesh_term>
	<mesh_term>Morphine</mesh_term>
	<mesh_term>Ketamine</mesh_term>
	<mesh_term>Chitosan</mesh_term>
	<criteria>Cancer pain outpatient : Opioid base therapy due pain Breakthrough pain Extreme pain movement Age &gt; = 18 year Patients unable give write informed consent Patients unable understand handle document use study medication Known drug allergy intolerance ketamine Known drug allergy intolerance morphine Known allergy crustacea chitosan Patients use snuff regular basis Recreational drug addiction abuse Serious intranasal epipharyngeal Problems ( Septum wall defect , cancer ) Mental/psychiatric disorder Patients renal failure ( clearance &lt; 30 ml/min ) Pregnancy breast feed mother Patients understanding German Patient arterial hypertonia measure value &gt; 180/95</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>